Global Liver Institute - GLI

What Global Liver Institute - GLI does

Global Liver Institute (GLI) is a 501(c)(3) nonprofit advocacy organization founded in 2015 and headquartered in Washington, D.C., that operates as a convener and catalyst for liver disease innovation. The organization does not build proprietary technology products; instead it runs a platform of interconnected programs organized around four strategic councils (Fatty Liver Disease, Liver Cancers, Pediatric & Rare Liver Diseases, and a Patient & Scientific Advisory Council) and several branded initiatives including the Advanced Advocacy Academy (A3), Beyond the Biopsy, Liver Health is Public Health, Liver Health for Veterans, the Liver Health Symposium, and the Global Fatty Liver Day campaign. GLI's core technology stack is non-existent in the conventional sense — its operational assets are a website (globalliver.org), social media channels, email newsletters, an interactive Fatty Liver Risk Assessment Quiz, and a federated distribution network of 20+ Liver Action Network affiliate organizations that localize its programs.

GLI serves five primary stakeholder groups: liver disease patients and caregivers, healthcare providers, government policymakers, researchers, and healthcare industry partners. The organization's go-to-market is community-led rather than commercial — it operates through patient advocate training (A3), CME-accredited symposiums, in-person events (Liver Health Symposium in Orlando, FL; A3 UK in London), and high-level policy engagement at the World Health Assembly, UN General Assembly, and EU Parliament. The Liver Action Network functions as a channel/reseller structure, distributing GLI resources through affiliated national liver organizations across the Americas, Europe, Africa, Asia, the Middle East, and Oceania.

Revenue is generated entirely through donations and corporate sponsorships, with disclosed industry supporters including Salix Pharmaceuticals, Sanofi, Opella, Novo Nordisk, Boehringer Ingelheim, Echosens, Madrigal Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, and Pfizer. No products or services are sold; resources, training, and educational content are provided free of charge. GLI is governed by a Board of Directors led by Chair Victor J. Reyes, Treasurer Brian Munroe, and Secretary Shonta Chambers, with Larry R. Holden serving as President and CEO. The organization operates with a lean 1-10 person staff, leveraging 233+ trained A3 alumni and 150+ partner organizations to deliver programs across 75+ countries on five continents.

Name

Global Liver Institute - GLI

Legal name

Global Liver Institute

Website

https://globalliver.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Global Liver Institute is a 501(c)(3) nonprofit that convenes policymakers, clinicians, industry, and patients through four strategic councils and programs like the Advanced Advocacy Academy to drive global liver disease advocacy and policy.

Ownership category

akta.pro rank

Product category

Liver Health Advocacy

akta.pro primary industry

Hepatology & Liver Disease (HLAKAEAB)

Keywords

• Liver health advocacy
• Patient advocacy training
• Public health policy
• Liver disease awareness
• Nonprofit health education

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: GLI operates as a 501(c)(3) nonprofit organization funded primarily through donations from individuals, foundations, and corporate partners. The organization promotes innovation, encourages collaboration, and supports scaling optimal approaches to help eradicate liver diseases.
2. Corporate Sponsorships and Partnerships: GLI receives support from pharmaceutical and healthcare companies including Salix Pharmaceuticals, Sanofi, Opella, Novo Nordisk, Boehringer Ingelheim, Echosens, and others who support specific programs and initiatives such as the Liver Health is Public Health campaign.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

Global Liver Institute is a nonprofit advocacy organization that delivers patient advocacy training, public health education, and policy convening services focused on liver disease. Its core offerings include the Advanced Advocacy Academy (A3) training program, awareness campaigns (Global Fatty Liver Day, #OctoberIs4Livers, #RareAware), policy and education initiatives (Liver Health is Public Health, Beyond the Biopsy, Liver Health for Veterans), three strategic disease councils, and the Liver Action Network of partner organizations.

Product overview

Global Liver Institute (GLI) is a nonprofit organization that operates as a platform of interconnected programs, initiatives, and councils rather than a single product. The organization centers on four strategic councils (Fatty Liver Disease, Liver Cancers, and Pediatric and Rare Liver Diseases) that bring together experts, advocates, and stakeholders. Core programs include the Advanced Advocacy Academy (A3) for patient advocate training, Beyond the Biopsy initiative for non-invasive diagnostics, Liver Health Symposium for education and CME credits, and Liver Health is Public Health initiative for policy advocacy. GLI also runs awareness campaigns including Global Fatty Liver Day, #OctoberIs4Livers, and #RareAware, along with the Liver Action Network affiliate program. Publications include the Global State of Liver Health Report and Best Practices in Liver Health Policy Report series.

Differentiator

Problem solved

Functional benefit

Brands

• Global Fatty Liver Day: A global public education and awareness campaign on steatotic (fatty) liver disease, observed annually on the second Thursday of June.
• Advanced Advocacy Academy (A3)
• Beyond the Biopsy
• Liver Health Symposium
• Liver Health is Public Health
• Liver Action Network
• #OctoberIs4Livers
• #RareAware

Products and services

• Advanced Advocacy Academy (A3) Year-round training program and annual learning and advocacy experience that empowers patient advocates to speak with clarity and impact on policies and systems affecting liver health. Open to patient advocates, caregivers, and community champions seeking to influence liver health policy.
• Beyond the Biopsy Initiative that promotes the widespread adoption of non-invasive diagnostic tools to address fatty liver disease, targeting expanded use in primary care, community clinics, emergency departments, and rural healthcare settings. Aimed at clinicians, health systems, and policymakers.
• Liver Health Symposium One-day in-person event uniting patients, caregivers, healthcare providers, and advocates. Features a community health fair, free liver health screening, and two tailored learning tracks with CME credits available for providers. Held in partnership with Mayo Clinic and local specialists.
• Liver Health is Public Health Global initiative that elevates liver health as a critical public health priority through interaction with international advocacy groups, doctors, healthcare practitioners, liver patient advocates, and ambassadors. Aimed at policymakers and underserved communities.
• Liver Health for Veterans Program supporting U.S. Veterans with tailored education, advocacy, and access to liver health resources to help them navigate risk factors, obtain timely care, and protect long-term wellbeing.
• Global Fatty Liver Day Annual global public education and awareness campaign observed on the second Thursday of June, mobilizing patients, governments, healthcare providers, and industry partners to spotlight steatotic (fatty) liver disease.
• #OctoberIs4Livers Annual campaign uniting the liver cancer community in a global conversation to raise awareness and drive progress against liver cancers, organized around education, prevention, detection, and survivorship pillars.
• #RareAware Annual Rare Liver Diseases Month campaign promoting awareness and education about rare liver diseases through discussions on health policies, education, and advocacy, addressing barriers and challenges to patient access and care.
• Liver Action Network (LAN) Global network of 20+ affiliate organizations united to improve liver health. Members create patient-focused resources, host trainings, facilitate health screenings and awareness events, advise on nutrition and care pathways, and share legislative priority updates.
• Fatty Liver Disease Council Council uniting 70+ organizations and stakeholders including patient advocacy groups, medical societies, and government agencies to identify gaps, address critical public health issues, and champion patient-focused solutions for fatty liver disease.
• Liver Cancers Council Council uniting 60+ organizations and stakeholders including advocacy partners, healthcare professionals, patients, survivors, and advocates to identify gaps, address critical public health issues, and champion patient-focused solutions for liver cancer.
• Pediatric and Rare Liver Diseases Council Council bringing together nonprofit, for-profit, government, and patient representatives committed to addressing the challenges and impact of pediatric and rare liver diseases on individuals, communities, and organizations worldwide.
• Fatty Liver Risk Assessment Quiz Interactive online quiz that helps individuals determine whether they may be at risk for MASLD (Metabolic dysfunction-associated steatotic liver disease) or MASH, and provides educational information and guidance on next steps for liver health.

Quantifiable outcome

• 233+ patient advocates trained through Advanced Advocacy Academy program since 2017
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

22 partnerships are on record, tiered core, flagship and major.

• King's College Hospital NHS Foundation TrustcoreStrategic or Co-development PartnerGLI partners with King's College Hospital NHS Foundation Trust for the Advanced Advocacy Academy (A3) UK program, held April 10-11, 2026 at the Royal Society of Medicine in London. King's College Hospital is recognized internationally for its work in liver disease and transplantation. Dr. Saima Ajaz, Specialist Hepatologist at King's College Hospital, serves as course director for the A3 UK program.
• British Liver TrustcoreStrategic or Co-development PartnerBritish Liver Trust joined as a new partner for A3 UK 2026, joining GLI and King's College Hospital NHS Foundation Trust. The British Liver Trust is the leading liver charity in the UK, working to save lives and improve liver health. The partnership creates a unified platform to advance liver health in the UK while advancing global advocacy, clinical leadership, and national representation.
• Egyptian Ministry of Health and PopulationflagshipStrategic or Co-development PartnerGLI collaborated with the Egyptian Ministry of Health and Population to convene a high-level policy event at WHA79 in Geneva, bringing together Ministers of Health from Bangladesh, China, Egypt, Qatar, and the Russian Federation. The event advanced implementation priorities for SLD as a global public health priority and launched the third edition of the Best Practices in Liver Health Policy report.
• EchosensmajorGTM or Marketing PartnerEchosens is a sponsor of GLI's Liver Health is Public Health initiative and is listed as a supporter of GLI's global policy work. Echosens develops non-invasive diagnostic technologies for liver health assessment.
• Madrigal PharmaceuticalsmajorGTM or Marketing PartnerMadrigal Pharmaceuticals is a supporter of GLI's global policy work and liver health initiatives. Madrigal is a biopharmaceutical company focused on developing treatments for metabolic liver diseases.
• Salix PharmaceuticalsmajorGTM or Marketing PartnerSalix Pharmaceuticals is a supporter of the Liver Health is Public Health initiative. Salix Pharmaceuticals specializes in gastroenterology and hepatology products.
• SanofimajorGTM or Marketing PartnerSanofi is a supporter of the Liver Health is Public Health initiative. Sanofi is a global pharmaceutical company engaged in developing and delivering healthcare solutions.
• OpellamajorGTM or Marketing PartnerOpella (formerly Sanofi Consumer Healthcare) is a supporter of the Liver Health is Public Health initiative.
• Novo NordiskmajorGTM or Marketing PartnerNovo Nordisk is a supporter of the Liver Health is Public Health initiative. Novo Nordisk is a global healthcare company focused on diabetes, obesity, and other chronic diseases.
• Boehringer IngelheimmajorGTM or Marketing PartnerBoehringer Ingelheim is a supporter of the Liver Health is Public Health initiative. Boehringer Ingelheim is a research-driven pharmaceutical company.
• AstraZenecamajorGTM or Marketing PartnerAstraZeneca is listed as a contributor to GLI, supporting the organization's mission to advance liver health globally.
• Bristol Myers SquibbmajorGTM or Marketing PartnerBristol Myers Squibb is listed as a contributor to GLI, supporting liver health programs and initiatives.
• Gilead SciencesmajorGTM or Marketing PartnerGilead Sciences is listed as a contributor to GLI, supporting pediatric and rare liver disease initiatives.
• PfizermajorGTM or Marketing PartnerPfizer is listed as a contributor to GLI, supporting liver health advocacy and education.
• European Association for the Study of the Liver (EASL)coreStrategic or Co-development PartnerEASL co-hosted GLI's policy event at WHA78 and endorsed GLI's Call to Action for SLD recognition. EASL is a leading international liver disease association.
• American Association for the Study of Liver Diseases (AASLD)coreStrategic or Co-development PartnerAASLD co-hosted GLI's policy event at WHA78 and endorsed GLI's Call to Action for SLD recognition. AASLD is the leading U.S. liver disease professional organization.
• Liver Cancers Council Members (60+ organizations)coreStrategic or Co-development PartnerThe Liver Cancers Council includes 60+ member organizations including AstraZeneca, Bristol Myers Squibb, Cancer Support Community, Genentech, Prevent Cancer Foundation, and others working collaboratively to improve the liver cancer experience.
• Fatty Liver Disease Council Members (70+ organizations)coreStrategic or Co-development PartnerThe Fatty Liver Disease Council includes 70+ member organizations including AASLD, American Heart Association, American Diabetes Association, EASL, WHO, and others championing fatty liver disease as a public health concern.
• Pediatric and Rare Liver Diseases Council Members (40+ organizations)coreStrategic or Co-development PartnerThe Pediatric and Rare Liver Diseases Council includes 40+ member organizations including EASL, Children's PSC Foundation, PBC Foundation, Takeda, Gilead, and others addressing challenges of pediatric and rare liver diseases.
• Liver Action Network Members (20+ organizations)majorStrategic or Co-development PartnerLAN includes 20+ affiliate organizations including American Liver Foundation, Fatty Liver Foundation, Biliary Atresia and Liver Care Africa, LiverWell Australia, Texas Liver Care, and others united to improve liver health through local outreach and advocacy.
• Society Hepatos (Croatia)majorStrategic or Co-development PartnerGLI partnered with Croatian Society for Liver Diseases 'Hepatos' to convene the Croatia Roundtable on Liver Health in Zagreb, February 2026, bringing together national and international stakeholders to strengthen recognition of liver disease as a public health priority.
• Croatian Society of HepatologymajorOthersGLI partnered with Croatian Society for Liver Diseases 'Hepatos' for the Croatia Roundtable on Liver Health, addressing the full spectrum of liver diseases including viral hepatitis, alcohol-related liver disease, liver cancer, and SLD.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• National Organization for Rare Disorders (NORD): The U.S. umbrella organization for the rare disease community and a GLI partner. Comparable as a chronic/rare disease advocacy convener with policy engagement, but operates at a much larger scale and across all rare diseases rather than liver-specific.
• American Diabetes Association: A large chronic disease nonprofit with global policy engagement, research funding, and patient advocacy. Highly relevant as a comparable operating model given the metabolic-disease overlap between diabetes and MASLD — increasingly a co-advocacy territory for GLI.
• American Heart Association: A massive chronic disease advocacy nonprofit operating a comparable model (public education, policy advocacy, fundraising, multi-stakeholder convening). GLI's strategic approach mirrors AHA's playbook adapted for liver disease, making it a relevant model peer.
• American Association for the Study of Liver Diseases (AASLD): The leading U.S. professional medical society for hepatology. Co-hosted GLI's WHA policy events and endorsed its SLD Call to Action. Overlaps with GLI in policy advocacy and clinical education but operates as a clinician-focused incumbent rather than patient-advocacy specialist.
• European Association for the Study of the Liver (EASL): Europe's leading hepatology professional association. Co-hosts GLI's WHA policy events and is a council member. Comparable as a global liver advocacy/policy stakeholder but with a clinician-researcher membership base rather than patient-advocacy orientation.

Direct peers

• Fatty Liver Foundation: A U.S. nonprofit focused specifically on fatty liver disease (MASLD/MASH) patient education and advocacy. A Liver Action Network affiliate with highly overlapping mission and patient base — the closest pure-direct competitor to GLI's fatty liver portfolio.
• American Liver Foundation: The largest U.S.-based liver disease patient advocacy nonprofit. A core member of GLI's Liver Action Network and operates in an overlapping mission space — patient education, advocacy, and liver disease awareness — making it the most directly comparable peer.
• Hepatitis B Foundation: A global nonprofit focused on hepatitis B awareness, research, and patient advocacy. Overlaps with GLI in liver disease patient advocacy and policy engagement, particularly around viral hepatitis — a vertical that GLI also addresses.
• British Liver Trust: The UK's leading liver charity and a strategic partner of GLI for the A3 UK program. Directly comparable in mission (liver disease advocacy, patient support, policy) and increasingly operationally aligned through joint programming.

Regional players

• LiverWell Australia: Australia's leading liver-focused patient advocacy organization and a Liver Action Network affiliate. Comparable mission and programs but geographically focused on Australia, making it a regional rather than global peer to GLI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCLYtkzOVI9GuFMPuEVde8vA
• Facebookfacebook.com/GlobalLiver
• LinkedInlinkedin.com/company/global-liver-institute
• Instagraminstagram.com/globalliverinstitute
• Xx.com/GlobalLiver

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Liver Institute - GLI